Ioflupane (123I)
Clinical data
Trade namesDaTscan
Other namesIoflupane (FPCIT);
[I-123] N-ω-fluoropropyl- 2β-carbomethoxy- 3β-(4-iodophenyl) nortropane
AHFS/Drugs.comProfessional Drug Facts
License data
  • X
Routes of
ATC code
Legal status
Legal status
  • US: Rx-only[1]
Pharmacokinetic data
ExcretionRenal and fecal
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass427.285 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Ioflupane (123I) is the International Nonproprietary Name of a cocaine analogue which is a neuro-imaging radiopharmaceutical drug, used in nuclear medicine for the diagnosis of Parkinson's disease and the differential diagnosis of Parkinson's disease over other disorders presenting similar symptoms. It is injected into a patient and viewed with a gamma camera in order to acquire SPECT images of the brain with particular respect to the striatum, a subcortical region of the basal ganglia.[2] The drug is sold under the tradename DaTscan and is manufactured by GE Healthcare, formerly Amersham plc. It is not marketed outside Europe and the United States.[1]

SPECT DaTSCAN showing normal Ioflupane (123I) uptake in the striatum.


Datscan is a solution of ioflupane (123I) for injection into a living test subject.

The iodine introduced during manufacture is a radioactive isotope, iodine-123, and it is the gamma decay of this isotope that is detectable to a gamma camera. 123I has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an appropriate radionuclide for medical imaging. The solution also contains 5% ethanol to aid solubility and is supplied sterile since it is intended for intravenous use.

Ioflupane has a high binding affinity for presynaptic dopamine transporters (DAT) in the brains of mammals, in particular the striatal region of the brain. A feature of Parkinson's disease is a marked reduction in dopaminergic neurons in the striatal region. By introducing an agent that binds to the dopamine transporters a quantitative measure and spatial distribution of the transporters can be obtained.[citation needed]

Method of administration[edit]

The Datscan solution is supplied ready to inject with a certificate stating the calibration activity and time. The nominal injection activity is 185 MBq[2] and a scan should not be performed with less than 111 MBq.

Thyroid blocking via oral administration of 120 mg potassium iodide is recommended to minimize unnecessary excessive uptake of radioiodine.[3] This is typically given 1-4 hours before the injection.[2][4]

The most convenient way to administer the IV dose is via a peripheral intravenous cannula. The scan is carried out 3 to 6 hours post injection.[3][4]


Common side effects of ioflupane (123I) are headache, vertigo, increased appetite and formication. Less than 1% of patients experience pain at the injection site.[2]

The radiation risks are reported as low. The committed effective dose for a single investigation on a 70 kg individual is 4.6 mSv.[5] Pregnant patients should not undergo the test. It is not known if 123I-ioflupane is secreted in breast milk however it is recommended that breastfeeding is interrupted for three days after administration.[2]

See also[edit]


  1. ^ a b "Removal of [123I]Ioflupane From Schedule II of the Controlled Substances Act". DEA Diversion Control Division. Archived from the original on 13 May 2017. Retrieved 2016-02-09.
  2. ^ a b c d e "DaTSCAN Summary of Product Characteristics" (PDF). European Medicines Agency. GE Healthcare. 25 July 2019.
  3. ^ a b Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. (February 2010). "EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2". European Journal of Nuclear Medicine and Molecular Imaging. 37 (2): 443–50. doi:10.1007/s00259-009-1267-x. PMID 19838702.
  4. ^ a b Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. (January 2012). "SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0". Journal of Nuclear Medicine. 53 (1): 154–63. doi:10.2967/jnumed.111.100784. PMID 22159160.
  5. ^ "Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources". ARSAC. Public Health England. 13 February 2019.

External links[edit]